Guillon J M, Thievant P, Braquet P
IHB/IPSEN, Le Plessis-Robinson, France.
Arch Mal Coeur Vaiss. 1989 Nov;82 Spec No 4:151-4.
Cicletanine is a new antihypertensive agent. In view of its various pharmacological properties and of the different factors involved in sudden death, cicletanine was tested on an ischaemia-reperfusion model in anaesthesized dogs. In these experiments myocardial reperfusion induced ventricular fibrillation in 87 p. 100 of the cases, where as only 20% of those animals who received cicletanine 20 mg/kg intravenously 15 minutes before the 30 minute coronary occlusion developed ventricular disorders (p less than 0.001 vs controls). Moreover, cicletanine showed good antiarrhythmic activity during occlusion (total number of arrhythmias: 73.0 +/- 23.15 in treated animals, as against 293.4 +/- 40.03 in controls; p less than 0.05). Thus, antihypertensive treatment with cicletanine may prevent some of the cardiovascular risks associated with arterial hypertension.
西氯他宁是一种新型抗高血压药物。鉴于其多种药理特性以及与猝死相关的不同因素,在麻醉犬的缺血-再灌注模型上对西氯他宁进行了试验。在这些实验中,心肌再灌注在87%的病例中诱发了心室颤动,而在冠状动脉闭塞30分钟前15分钟静脉注射20mg/kg西氯他宁的动物中,只有20%出现了心室紊乱(与对照组相比,p<0.001)。此外,西氯他宁在闭塞期间显示出良好的抗心律失常活性(治疗组动物心律失常总数:73.0±23.15,而对照组为293.4±40.03;p<0.05)。因此,用西氯他宁进行抗高血压治疗可能预防一些与动脉高血压相关的心血管风险。